Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;40(5):699-707.
doi: 10.1007/s10875-020-00789-4. Epub 2020 May 23.

Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy

Nicholas J Gloude  1   2 , Christopher E Dandoy  3   4 , Stella M Davies  3   4 , Kasiani C Myers  3   4 , Michael B Jordan  3   4 , Rebecca A Marsh  3   4 , Ashish Kumar  2   3 , Jack Bleesing  3   4 , Ashley Teusink-Cross  4   5 , Sonata Jodele  6   7
Affiliations

Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy

Nicholas J Gloude et al. J Clin Immunol. 2020 Jul.

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of excessive immune system activation driven mainly by high levels of interferon gamma. The clinical presentation of HLH can have considerable overlap with other inflammatory conditions. We present a cohort of patients with therapy refractory HLH referred to our center who were found to have a simultaneous presentation of complement-mediated thrombotic microangiopathy (TMA). Twenty-three patients had therapy refractory HLH (13 primary, 4 EVB-HLH, 6 HLH without known trigger). Sixteen (69.6%) met high-risk TMA criteria. Renal failure requiring renal replacement therapy, severe hypertension, serositis, and gastrointestinal bleeding were documented only in patients with HLH who had concomitant complement-mediated TMA. Patients with HLH and without TMA required ventilator support mainly due to CNS symptoms, while those with HLH and TMA had respiratory failure predominantly associated with pulmonary hypertension, a known presentation of pulmonary TMA. Ten patients received eculizumab for complement-mediated TMA management while being treated for HLH. All patients who received the complement blocker eculizumab in addition to the interferon gamma blocker emapalumab had complete resolution of their TMA and survived. Our observations suggest co-activation of both interferon and complement pathways as a potential culprit in the evolution of thrombotic microangiopathy in patients with inflammatory disorders like refractory HLH and may offer novel therapeutic approaches for these critically ill patients. TMA should be considered in children with HLH and multi-organ failure, as an early institution of a brief course of complement blocking therapy in addition to HLH-targeted therapy may improve clinical outcomes in these patients.

Keywords: Complement; Eculizumab; Emapalumab; Hemophagocytic lymphohistiocytosis; Interferon gamma; Thrombotic microangiopathy.

PubMed Disclaimer

Conflict of interest statement

NJG, CED, RAM, and JB have no interests to disclose. SJ and SMD have US patents pending. MBJ and AK are consultants for Sobi. ATC is on the speaker’s bureau for Sobi. None of these funding sources had any input in the study design, analysis, manuscript preparation, or decision to submit for publication.

Figures

Fig. 1
Fig. 1
Outcomes of patients with HLH based on treatment received
Fig. 2
Fig. 2
TMA evaluation schema for patients with clinical diagnosis of HLH
See this image and copyright information in PMC

References

    1. Buatois V, Chatel L, Cons L, Lory S, Richard F, Guilhot F, Johnson Z, Bracaglia C, De Benedetti F, de Min C, Kosco-Vilbois MH, Ferlin WG. Use of a mouse model to identify a blood biomarker for IFNgamma activity in pediatric secondary hemophagocytic lymphohistiocytosis. Transl Res. 2017;180:37–52. doi: 10.1016/j.trsl.2016.07.023. - DOI - PMC - PubMed
    1. Prencipe G, Caiello I, Pascarella A, Grom AA, Bracaglia C, Chatel L, Ferlin WG, Marasco E, Strippoli R, de Min C, De Benedetti F. Neutralization of IFN-gamma reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. J Allergy Clin Immunol. 2018;141:1439–1449. doi: 10.1016/j.jaci.2017.07.021. - DOI - PubMed
    1. Henter JI, Elinder G, Soder O, Hansson M, Andersson B, Andersson U. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991;78:2918–2922. doi: 10.1182/blood.V78.11.2918.2918. - DOI - PubMed
    1. Xu XJ, Tang YM, Song H, Yang SL, Xu WQ, Zhao N, Shi SW, Shen HP, Mao JQ, Zhang LY, Pan BH. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr. 2012;160:984–990. doi: 10.1016/j.jpeds.2011.11.046. - DOI - PubMed
    1. Bracaglia C, de Graaf K, Pires Marafon D, Guilhot F, Ferlin W, Prencipe G, Caiello I, Davi S, Schulert G, Ravelli A, Grom AA, de Min C, De Benedetti F. Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2017;76:166–172. doi: 10.1136/annrheumdis-2015-209020. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources